| 前收市價 | 56.03 |
| 開市 | 56.04 |
| 買盤 | 55.79 x 1200 |
| 賣出價 | 56.19 x 1200 |
| 今日波幅 | 55.79 - 56.07 |
| 52 週波幅 | 31.45 - 60.20 |
| 成交量 | |
| 平均成交量 | 2,755,935 |
| 市值 | 10.125B |
| Beta 值 (5 年，每月) | 1.19 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -7.18 |
| 業績公佈日 | 2024年5月17日 - 2024年5月21日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 56.70 |
ZacksCharles River (CRL) Forges Collaboration With Ship of Theseus
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
ReutersNovo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent, a spokesperson said on Monday. Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion.
- Reuters
UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday. Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion.
